Method of inhibiting inflammatory response
AssigneeThe Regents of the University of California
InventorsEdward T. Wei, Juliann G. Kiang
Life of this patent
Estimating the term…
Abstract
Many malignant neoplasias are treated by radiation therapy which can result in painful inflammation of the covering skin and/or mucosal membranes. Similarly, skin disorder patients receiving U.V. treatment may experience an inflammatory response. Certain neuropeptides have been discovered to have the unusual properties of preventing, or inhibiting, the edema and protein extravasation of skin and mucosal membrane injuries due to thermal or radiation assault or exposure to trauma or noxious agents. A method for inhibiting an inflammatory response in the skin or mucosal membranes of a patient is provided in which a therapeutically effective amount of a neuropeptide, such as Corticotropin Releasing Factor ("CRF") or its analogs, is administered.
Claims11
A method of treating skin or mucosal membrane inflammation of a mammal comprising:
- administering an anti-inflammatory amount of a neuropeptide effective in inhibit inflammationof th eskin and mucosal membranes of a mammal, the neuropeptide consisting essentially of Corticotropin Releasing Factor, and analog thereof, or a non-toxic salt of the Corticotropin Releasing Factor or analog.
A method for inhibiting an inflammatory response in the skin or mucosal membranes of a patient comprising:
- administering at least about 1 .mu.g per kg of patient's body weight of a neuropeptide prior to, during or after the the patient's skin or mucosal membrane is exposed to heat, radiation or a noxious substance, the administered neuropeptide being effective to inhibit an inflammatory response to the exposure, the neuropeptide administered consisting essentially of Corticotropin Releasing Factor, an analog thereof, or a non-toxic salt of the Corticotropin Releasing Factor or analog.
Dependencies are inferred from the claim text.